BD Biosciences to Expand Manufacturing in Durham, North Carolina
News May 14, 2007
BD Biosciences, a segment of BD (Becton, Dickinson and Company), has announced plans to expand its Treyburn facility in Durham, North Carolina to consolidate and increase U.S. manufacturing capacity for its Discovery Labware products, including BD Falcon™ products.
The $25 million capital investment project is expected to create 28 new positions in 2007 and a total of 100 by the end of 2008, building on a presence of approximately 285 employees today.
With expertise in fluid handling, tissue culture, and cell screening, BD Biosciences - Discovery Labware provides products and services with applications for drug discovery, high throughput screening, angiogenesis and tumor invasion.
The new capacity is intended to meet growing demand for BD Falcon™ tubes, pipettes, plates, cell inserts, and other products used in life science research settings. Approximately 50,000 square feet of manufacturing space will be added, directly contiguous to existing production lines.
“Treyburn offers an ideal platform as BD looks to increase capacity to meet demand for our Discovery Labware products,” said Todd Shackett, Plant Manager of the Treyburn facility. “We are able to build upon our own successful manufacturing operations, as well as the pool of high-tech expertise in this region. We couldn’t be more pleased to be growing in Durham. Today’s moves will provide the cornerstone for future development.”
Bill Kozy, Executive Vice President, added: “This expansion will allow BD to meet growing demand for class-leading products that are critical tools for life science researchers everywhere, while also enabling us to optimize our global production and supply chains for related products.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE